2Şanlıurfa Balıklıgöl State Hospital, Biochemistry Laboratory, Şanlıurfa, Turkey
3Department of Clinical Biochemistry, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey
4Department of Clinical Biochemistry, Ankara Training and Research Hospital, Ankara, Turkey
5Department of Biostatistics and Medical Informatics, Erciyes University School of Medicine, Kayseri, Turkey
Abstract
Objective[|]Factor V (FV) (1691 G-A) and methylenetetrahydrofolate reductase (MTHFR) (677 C-T) mutations have been identified as potential risk factors for cardiovascular disease. In this study, we determined vitamin B12, folate, and total homocysteine t(Hcy) concentrations in heterozygote MTHFR (677 C-T) and FV (1691 G-A) mutation-carrying individuals.[¤]Materials and Methods[|]The study included a total of 74 individuals with MTHFR (677 C-T) or FV (1691 G-A) mutations and 70 controls. All subjects had the history of thromboembolic disease. t(Hcy), folate, and vitamin B12 concentrations were compared between the groups.[¤]Results[|]A significant difference was found in vitamin B12 and folate concentrations between patients and controls in the MTHFR (677 C-T) group (p=0.041, p=0.049, respectively). Further, t(Hcy) concentrations were found to be higher in patients than in controls in the FV (1691 G-A) mutation-carrying group (p=0.002). No significant difference was found between the groups in relation with gender in both mutations.[¤]Conclusion[|]t(Hcy) concentrations should be assessed to decrease the risk of future venous thromboembolism in the presence of heterozygote FV (1691 G-A) mutation.[¤]